4th Midkine Symposium April 2016: Bringing together Midkine researchers from around the globe




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: 4th Midkine Symposium April 2016: Bringing together Midkine researchers from around the globe
Released on: June 27, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Maria Halasz, CEO and Managing Director of Cellmid discusses the Midkine Symposium and the company’s strategy around chronic kidney disease (CKD) and related complications and acute myocardial infarction (AMI).
  • Summary
  • Transcript
  • Participants
  • Company
Maria Halasz, CEO and Managing Director of Cellmid discusses the Midkine Symposium and the company’s strategy around chronic kidney disease (CKD) and related complications and acute myocardial infarction (AMI).
Maria Halasz, CEO and Managing Director of Cellmid discusses the Midkine Symposium and the company’s strategy around chronic kidney disease (CKD) and related complications and acute myocardial infarction (AMI).
Maria brings a world of experience – literally – to her directorships and management roles. She began her career as a 20-year-old migrant with little more than a love of biological sciences, part of a medical degree, and a can-do attitude. Since then she has become an accomplished public company CEO and on the way executed deals in the US, China, Japan, the UK and NZ as well as picking up a science degree and an MBA. Her reputation for successfully restructuring businesses was cemented by turning around Cellmid when it had been struggling seven years ago. She has restructured the debt, raised more money, attracted a new board of supportive and accomplished directors, and acquired an intellectual-property portfolio that is now on its way to breakthrough cancer therapies. She also saw an opportunity in a related consumer health field and created a subsidiary with international income streams. Cellmid is now generating revenue from its Australian and overseas businesses while at an exciting stage of developing cancer drugs and oncology diagnostic tests. To achieve these successes, Maria used all the skills she has honed throughout her 22-year corporate career in funds management, corporate finance and investment banking as well as in the product development, manufacturing and consumer health industries. She has developed skills to solve complex problems, an ability that came from spending years in industries with multiple regulatory, structural and market constraints. Maria is a graduate of the Australian Institute of Company Directors, has board experience in listed public, unlisted and private companies, and acted on advisory boards of non-profit organisations. She has specific experience in finance, initial public offerings, mergers and acquisitions and most facets of the life sciences sector.
Cellmid
Cellmid is an Australian biotechnology company developing innovative new therapies and diagnostic tests for heart attack, inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. Midkine is a cytokine that promotes cell migration, growth and survival. Discovered over twenty years ago, midkine’s roles in inflammation and cell survival have been extensively validated by researchers worldwide. Elevated midkine concentration in the blood or other body fluids is strongly indicative of cancer. Cellmid’s first product is a blood test that sensitively and accurately measures serum midkine levels. As well as developing this test in-house, Cellmid is actively out-licensing its broad diagnostic patent portfolio for the early detection, monitoring, prognosis and disease monitoring of cancer. The Company’s most advanced clinical development program targets the treatment of heart attack (acute myocardial infarction or AMI) utilising the midkine protein and its anti-apoptotic characteristics. Cellmid is also humanising its lead anti-midkine antibody for the treatment of inflammatory and autoimmune disorders.